Ocular Therapeutix, Inc. (OCUL) Stock Price, Financial Report, & Fundamental Analysis

Strength

Analysis	#
Revenue Growth OCUL has had growing revenue for the last 5 years
Net Income Growth OCUL has had growing net income for the last 2 years
Revenue OCUL has positive revenue for last 5 years

Weakness

Analysis	#
Market Cap Small market capitalization. Market capitalization is less than 2bn USD
Price to Book (PBV) Ratio Overvalued price-to-book. OCUL stock price is overvalued by more than 2x the price-to-book value.
Net Income OCUL never has positive net income for 2 years.
Debt-Equity Ratio (DER) OCUL debt is 2.43x it's equity.
Dividend Yield OCUL has low dividend yield (0%).
Return of Assets OCUL has low return of asset (-37.42%).
Return of Equity OCUL has low return of equity (-84.83%).
Return of Invested Capital OCUL has low ROIC.

Competitors

Financial statements are written records that convey the business activities and the financial performance of a company. Financial statements include the balance sheet, income statement, and statement of cash flow.

Income Statement

Also known as the profit and loss (P&L) statement or the statement of revenue and expense, the income statement primarily focuses on the company’s revenue and expenses during a particular period.

Cashflow Statement

A cash flow statement is a financial statement that provides aggregate data regarding all cash inflows a company receives from its ongoing operations and external investment sources. It also includes all cash outflows that pay for business activities and investments during a given period.

Free Cash Flow

-66,744,000 USD

Dividend

Financial Ratios

CEO

CEO Name

Mr. Antony Mattessich

Management

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Additional Information

Company name

Ocular Therapeutix, Inc.

Symbol

NASDAQ:OCUL

Exchange

NASDAQ Global Market

Industry

Biotechnology

Sector

Healthcare

Address

24 Crosby Dr
Bedford
MASSACHUSETTS
US
01730

Website

https://www.ocutx.com